SCHEMBL3071006

SCHEMBL3071006

CCN(CC)c1ccc(CN(C(C)=O)c2ccc(F)cc2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 2/20 0.47
AOC3 Q16853 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK14 Q16539 1/20 0.41
LTB4R2 Q9NPC1 3/20 0.40
CYP3A4 P08684 2/20 0.40
GBA1 P04062 1/20 0.39
BCL2A1 Q16548 1/20 0.39
CNR2 P34972 1/20 0.39
CXCR1 P25024 1/20 0.38
CXCR2 P25025 1/20 0.38
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736030 0.90 CACNA1H (0.47) CACNA1HAOC3MEN1KMT2AMAPK14
SCHEMBL3064331 0.87 CACNA1H (0.45) CACNA1HAOC3MEN1KMT2ALTB4R2
SCHEMBL3815393 0.87 CACNA1H (0.45) CACNA1HAOC3LTB4R2CYP3A4GBA1
SCHEMBL3816063 0.86 CACNA1H (0.45) CACNA1HAOC3LTB4R2GBA1BCL2A1
SCHEMBL3825186 0.85 CACNA1H (0.44) CACNA1HAOC3MAPK14LTB4R2GBA1
SCHEMBL3063271 0.85 RIPK1 (0.49) CACNA1HAOC3LTB4R2GBA1BCL2A1
SCHEMBL3065942 0.84 CACNA1H (0.46) CACNA1HAOC3LTB4R2GBA1BCL2A1
SCHEMBL3821700 0.83 CNR2 (0.49) CACNA1HAOC3MAPK14LTB4R2BCL2A1
Trifluoroacetic Acid SCHEMBL3054195 0.82 CACNA1H (0.42) CACNA1HAOC3MEN1KMT2ALTB4R2
SCHEMBL3819450 0.82 CACNA1H (0.46) CACNA1HAOC3LTB4R2BCL2A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US claimed
EP-2099754-A1 ION CHANNEL MODULATORS Wyeth a Corporation of the State of Delaware (US) 2009-09-16 EP claimed
WO-2008073929-A1 ION CHANNEL MODULATORS WYETH (US) 2008-06-19 WO claimed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267697-A1 ION CHANNEL MODULATORS CACNA1E, CACNA1A, CACNA1S CACNA1H 13/4885AOC3 4426/4885MEN1 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.